Cumberland Pharmaceuticals (NASDAQ:CPIX) Coverage Initiated by Analysts at

Equities researchers at began coverage on shares of Cumberland Pharmaceuticals (NASDAQ:CPIXGet Free Report) in a research note issued on Wednesday. The brokerage set a “hold” rating on the specialty pharmaceutical company’s stock.

Cumberland Pharmaceuticals Price Performance

Shares of Cumberland Pharmaceuticals stock opened at $1.64 on Wednesday. The company has a debt-to-equity ratio of 0.44, a current ratio of 1.28 and a quick ratio of 1.11. Cumberland Pharmaceuticals has a one year low of $1.43 and a one year high of $2.36. The business’s 50 day simple moving average is $1.86 and its two-hundred day simple moving average is $1.88. The stock has a market capitalization of $23.25 million, a P/E ratio of -3.73 and a beta of 0.16.

Cumberland Pharmaceuticals (NASDAQ:CPIXGet Free Report) last issued its earnings results on Tuesday, March 5th. The specialty pharmaceutical company reported ($0.12) EPS for the quarter. The firm had revenue of $9.35 million during the quarter. Cumberland Pharmaceuticals had a positive return on equity of 6.84% and a negative net margin of 15.87%.

Institutional Trading of Cumberland Pharmaceuticals

A hedge fund recently bought a new stake in Cumberland Pharmaceuticals stock. Bank of New York Mellon Corp acquired a new position in Cumberland Pharmaceuticals Inc. (NASDAQ:CPIXFree Report) in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm acquired 75,268 shares of the specialty pharmaceutical company’s stock, valued at approximately $142,000. Bank of New York Mellon Corp owned 0.52% of Cumberland Pharmaceuticals as of its most recent filing with the Securities and Exchange Commission. 15.51% of the stock is currently owned by institutional investors and hedge funds.

Cumberland Pharmaceuticals Company Profile

(Get Free Report)

Cumberland Pharmaceuticals Inc, a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, and oncology in the United States and internationally. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of constipation; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duodenal ulcer disease; Vaprisol, an injection for treating euvolemic and hypervolemic hyponatremia; Sancuso, an injection for the treatment of chemotherapy treatment; and Vibativ, an injection for the treatment of certain serious bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections.

Read More

Receive News & Ratings for Cumberland Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cumberland Pharmaceuticals and related companies with's FREE daily email newsletter.